Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.

Synta Pharmaceuticals Corp has decided to end a late-stage trial of its lung cancer treatment after an independent review said it proved ineffective, nearly halving its stock in extended trading on Tuesday. Lexington, Massachusetts-based Synta’s shares were down 46.6 percent at $1.09 after the bell. The late stage study aimed to see if a combination […]